First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa-Reference-Cited by-同舟云学术

First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa

Published:2023-11-02 Issue:11 Volume:32 Page:1085-1094
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Wu Shuanzhi¹^ORCID,Wang Tenghua¹,Li Jieyun²,Zhang Zhixin¹,Li Chen¹,Xiao Shuangshuang¹,He Jin¹,Wang Xuan¹,Hu Zhiqin¹,Wang Xiaole¹,Zheng Sichao¹,Liang Xintong¹,Chen Guiying³,Li Yongmei¹,Li Xianbo¹,Zhan Yaoxuan¹,Zou Qinwen²,Jiang Hongliang³,Zheng Qingshan⁴,Ban Li¹,Liu Haiyan¹,Fang Yi¹⁵^ORCID

Affiliation:

1. Clinical Trial Institution, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

2. Beijing Lianxin Pharmaceutical Co., Ltd, Beijing, China

3. Wuhan Hongren Biomedical Co., Ltd, Wuhan, China

4. Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China

5. Clinical Trial Institution, Peking University People’s Hospital, Beijing, China

Funder

Beijing Lianxin Pharmaceutical Co., Ltd

the Major Project of National Science and Technology “Creation of Major New Drugs”

the Guangzhou Health Science and Technology Project

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2023.2283024

Reference24 articles.

1. Venous thromboembolism

2. Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications

3. Heparin induced thrombocytopenia: diagnosis and management update

4. Interactions of Warfarin with Drugs and Food

5. Direct oral anticoagulants: evidence and unresolved issues